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release of capsids into the cytoplasm is thought to involve
fusion of the viral envelope with either plasma or endosomal
membranes.
KSHV codes for a number of glycoproteins, some of which
have significant homology to glycoproteins of other herpesviruses. These include glycoprotein B (gB) (open reading frame
[ORF] 8 [ORF8]), gH (ORF22), gM (ORF39), gL (ORF47)
(36, 48), and gN (ORF53) (27). In addition, the K1, K8.1, and
vOX2 (K14) glycoproteins are unique to KSHV, with no counterparts in other herpesviruses (10, 11, 36, 49). KSHV gB and
glycoprotein K8.1A mediate the initial binding of virions to
glycosaminoglycans, e.g., heparan sulfate on cell surfaces (2, 4,
7, 57). In agreement with the strong binding of purified K8.1A
to heparan sulfate moieties on cell surfaces, initial studies
showed that a soluble form of K8.1A inhibited KSHV attachment to cells (57). However, a later report indicated that a
similar soluble form of K8.1A did not block KSHV infectivity
(7). In addition, gB binds to integrins, such as ␣3␤1-integrin
membrane receptors, through an RGD motif, suggesting that
integrins function as cellular receptors for KSHV entry (3, 34).
However, soluble integrins or RGD-containing peptides failed
to inhibit virus entry into 293 cells (22).
There are two ORFs originating from the K8.1 gene by
means of spliced transcripts, K8.1A and K8.1B. The K8.1A
cDNA encodes a 228-amino-acid protein containing a signal
sequence, transmembrane domain, and four N glycosylation
sites. The K8.1B cDNA encodes a 167-amino-acid glycoprotein
sharing similar amino and carboxy termini with K8.1A but
containing an in-frame deletion (10, 44). K8.1A is the predominant form detected within infected cells and virion envelopes

Kaposi’s sarcoma-associated herpesvirus (KSHV), also referred to as human herpesvirus 8, is a member of the gamma2-herpesvirus family (genus Rhadinovirus) (36, 48). KSHV is
etiologically associated with Kaposi’s sarcoma, primary effusion or body cavity-based lymphoma, and multicentric Castleman’s disease (6, 18, 49, 50). Recently, it was suggested that
KSHV may have a role in the development of primary pulmonary hypertension (14). KSHV can infect a variety of human
cell types, including B, T, endothelial, epithelial, fibroblast, and
keratinocyte cells, and nonhuman cell types, including owl
monkey kidney and baby hamster kidney fibroblast cells (9, 12,
16, 17, 19, 26, 29, 32, 33, 43, 45, 56, 61).
Generally, all herpesviruses initiate infection by means of
direct binding to various receptors on cell surfaces that is
mediated by several viral glycoproteins embedded in viral envelopes. Viral glycoproteins play important roles in virus attachment to susceptible cells, fusion of the viral envelope with
either cellular or endosomal membranes, and virion morphogenesis and egress (reviewed in references 25, 31, and 47).
Herpes simplex virus, human cytomegalovirus, and EpsteinBarr virus (EBV) have been shown to enter cells by either
pH-independent or pH-dependent pathways, depending on the
cell type (8, 13, 30, 37, 41, 47, 51). KSHV has been shown to
enter certain cells (human foreskin fibroblast cells and B cells)
by endocytosis (1, 4). Regardless of the mode of virus entry, the
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Kaposi’s sarcoma-associated herpesvirus (KSHV) is considered the etiologic agent of Kaposi’s sarcoma and
several lymphoproliferative disorders. Recently, the KSHV genome was cloned into a bacterial artificial chromosome and used to construct a recombinant KSHV carrying a deletion of the viral interferon regulatory factor
gene (F. C. Zhou, Y. J. Zhang, J. H. Deng, X. P. Wang, H. Y. Pan, E. Hettler, and S. J. Gao, J. Virol.
76:6185-6196, 2002). The K8.1 glycoprotein is a structural component of the KSHV particle and is thought to
facilitate virus entry by binding to heparan sulfate moieties on cell surfaces. To further address the role of K8.1
in virus infectivity, a K8.1-null recombinant virus (BAC36⌬K8.1) was constructed by deletion of most of the
K8.1 open reading frame and insertion of a kanamycin resistance gene cassette within the K8.1 gene. Southern
blotting and diagnostic PCR confirmed the presence of the engineered K8.1 gene deletion. Transfection of the
wild-type genome (BAC36) and mutant genome (BAC36⌬K8.1) DNAs into 293 cells in the presence or absence
of the complementing plasmid (pCDNAK8.1A), transiently expressing the K8.1A gene, produced infectious
virions in the supernatants of transfected cells. These results demonstrated that the K8.1 glycoprotein is not
required for KSHV entry into 293 cells.
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(62). The K8.1 gene has attracted significant interest due to the
fact that it is positionally colinear to the EBV major glycoprotein gp350/220 gene (20), the murine gammaherpesvirus 68
gp150 gene (53), the herpesvirus saimiri ORF51 gene (5), and
the bovine herpesvirus 4 BOEFD1 gene (36, 48). EBV gp350/
220 has been shown to be involved in the binding of the virus
to target cells by means of the CD21 receptor on B cells (15,
38–40, 55); however, gp350/220 is not required for virus entry
into fibroblasts (24).
Recently, the KSHV genome was cloned into a bacterial
artificial chromosome (BAC) and shown to produce infectious
virus (61). To resolve whether K8.1A functions in virus infectivity, we used the recombinant KSHV BAC36 as the initial
template to construct a K8.1-null virus to address the role of
K8.1 glycoproteins in the KSHV life cycle. Our data indicate
that both K8.1 glycoproteins are dispensable for virus entry.
MATERIALS AND METHODS
Cells and viruses. 293 cells were grown in Dulbecco’s modified Eagle medium
(DMEM; GIBCO-BRL, Grand Island, N.Y.) supplemented with 2 mM glutamine, 10% fetal calf serum, and antibiotics. KSHV BAC36 contains the green
fluorescent protein (GFP) gene cassette under the control of the human cytomegalovirus immediate-early promoter, constitutively expressing the GFP gene,
and inserted between KSHV ORF18 and KSHV ORF19 (61).
Immunofluorescence assays. The detection of K8.1A was monitored by indirect immunofluorescence with fluorescein isothiocyanate-conjugated goat antimouse immunoglobulin G, which detected the expression of the K8.1A plasmid
in transiently transfected 293 cells. Transfected cells were incubated for 48 h at
37°C and then fixed with cold methanol for 20 min. Monolayers were blocked for
1 h with 10% normal goat serum in phosphate-buffered saline (PBS), followed by
1 h of incubation with the primary monoclonal antibody (MAb) (60), 19B4,
directed against K8.1 proteins, at a dilution of 1:500. Cells were rinsed three
times with PBS and then incubated for 1 h with the secondary antibody, a
fluorescein-conjugated goat anti-mouse antibody (ICN Pharmaceuticals, Inc.,
Aurora, Ohio), at a dilution of 1:50. Cells were washed five times with PBS and
viewed with a fluorescence microscope.
Immunoblot analysis. Cell lysates of K8.1A-transfected 293 cells or induced
BCBL-1 cells were boiled in loading buffer (125 mM Tris-HCl, 2% sodium
dodecyl sulfate, 0.1% bromophenol blue, 1% 2-mercaptoethanol) for 5 min, and
the proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were electrotransferred to nitrocellulose membranes,
blocked with BLOTTO (5% nonfat milk in 0.01 M PBS–0.05% Tween 20), and
then reacted for 1 h with primary antibody MAb 19B4 (directed against K8.1A)
at a dilution of 1:1,000. A horseradish peroxidase-conjugated secondary antiserum at a dilution of 1:10,000 in PBS containing 10% goat serum was used. The
reaction was visualized with Western blotting chemiluminescence detection reagents (Pierce Inc., Rockford, Ill.).
Construction of a KSHV mutant with a deletion of the K8.1 gene
(BAC36⌬K8.1). Mutagenesis of BAC36 DNA was accomplished by using Escherichia coli and the  gam-recE-recT (GET) recombination system (35, 42).
Electrocompetent E. coli DH10B cells harboring BAC36 were transformed with
plasmid pGETrec, which contains the recE, recT, and bacteriophage  gam genes,
and grown on plates containing chloramphenicol (12.5 g/ml) and ampicillin
(100 g/ml). Individual colonies were picked and grown overnight in LuriaBertani (LB) medium containing chloramphenicol and ampicillin. On the next
day, the culture was used to inoculate 250 ml of LB medium containing chloramphenicol and ampicillin until an optical density at 600 nm of 0.4 was reached.
The addition of L-arabinose to a final concentration of 0.2% (wt/vol) and further
incubation for 40 min induced the expression of the recE, recT, and  gam genes
from plasmid pGETrec. The cells then were harvested and made electrocompetent.
A PCR fragment containing the kanamycin resistance gene flanked by 60 bp of
viral sequences on both sides was used for recombination to construct
BAC36⌬K8.1, containing a kanamycin resistance gene cassette within the targeted K8.1 genomic region. Briefly, electrocompetent DH10B cells (40 l),
harboring both BAC36 and pGETrec, were electroporated with 200 ng of purified PCR product to delete the target gene (K8.1 glycoprotein) by using standard
electroporation parameters (1.8 kV/cm, 200 ⍀, and 25 F). Following electro-
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poration, the cells were grown in 1 ml of LB medium for 60 min and then
streaked on LB agar plates containing both chloramphenicol (12.5 g/ml) and
kanamycin (50 g/ml). Episomal mutant BAC36 DNA containing the deletion in
either of the K8.1 genes by means of insertion of the kanamycin resistance gene
cassette was isolated from bacterial colonies, a second round of electroporation
was performed to remove plasmid pGETrec, and the cells were grown on agar
plates with chloramphenicol and kanamycin.
Confirmation of the K8.1 deletion in BAC36⌬K8.1 DNA. KSHV BAC DNAs
(BAC36 and BAC36⌬K8.1) were purified from 1 liter of BAC cultures by using
a large-construct kit (Qiagen, Valencia, Calif.). BAC DNA was digested with
KpnI and run on 0.8% agarose gels, and the restricted DNA was transferred to
charged nylon membranes (Bio-Rad, Richmond, Calif.). Southern blot hybridization was performed with a biotin-labeled kanamycin resistance gene probe by
labeling a 1.1-kb kanamycin PCR fragment with biotin (New England Biolabs,
Boston, Mass.). Chemiluminescence detection of the DNA was performed by
using a North2South chemiluminescence hybridization and detection kit as described by the manufacturer (Pierce Inc., Rockford, Ill.).
Transient transfection of KSHV BAC DNAs. Transient transfection of 293
cells with BAC DNAs was performed by using Superfect (Qiagen). 293 cells were
grown to 80% confluence in six-well plates. Cells were transfected with BAC
DNA mixed with Superfect in DMEM as recommended by the manufacturer.
After 4 h of incubation at 37°C, the medium was removed from the transfected
cells, and the cells were washed with PBS. Next, fresh DMEM with 10% fetal calf
serum was added.
Immunohistochemical staining. 293 cells in six-well plates were transfected
with BAC36 or BAC36⌬K8.1 DNA either alone or with the regulator of transcription activation (RTA) plasmid (cotransfection) for induction of the lytic
cycle. At 48 h after transfection, cells were washed with PBS, fixed with electron
microscopy-grade 2% paraformaldehyde (Electron Microscopy Sciences; Fort
Washington, Pa.) for 10 min, and then washed twice with PBS–50 mM glycine.
Blocking of cell monolayers for 1 h was performed with 5% normal goat serum
and 5% bovine serum albumin in PBS. Cells were incubated for 1 h with a
primary antibody, washed three times with PBS, and then incubated for 1 h with
a secondary antibody conjugated with biotin. Cells were washed three times with
PBS and then reacted with a 1:3,000 dilution of horseradish peroxidase-streptavidin in 10% goat serum for 1 h. Cells were washed five times, and Vector VIP
substrate was added (Vector Laboratories Inc., Burlingame, Calif.). Cells were
examined with a light microscope (Nikon Inc., Garden City, N.Y.). The primary
antibodies used in these studies were as follows: anti-K8.1 antibody 19B4 (60),
anti-ORF59 antibody, and anti-LANA antibody (Advanced Biotechnologies,
Inc., Columbia, Md.).
Production of infectious KSHV particles. 293 cells were transfected with either
BAC36, BAC36⌬K8.1, or EGFP-C1 DNA each mixed with ORF50 (RTA) and
either pCDNA3.1 (negative control plasmid) or pCDNAK8.1 (complementing
plasmid) in six-well plates. Transfected cells were induced with a final concentration of 25 ng of tetradecanoyl phorbol acetate (TPA) (Sigma, St. Louis,
Mo.)/ml and 1,000 U of alpha interferon (Sigma)/ml for 5 days. Supernatants
were collected from induced cell lines and centrifuged three times at 5,000 ⫻ g
for 15 min. Supernatants were frozen-thawed three times to eliminate any surviving cells. The viral supernatants were used for infection or quantitative PCR
analysis.
Infection of cells with harvested supernatants. Supernatants from transiently
transfected cells were used as viral inocula to infect cells at 80% confluence in a
96-well plate. Infection was performed in triplicate. A 50-l portion of infectious
viral inoculum with Polybrene added to a final concentration of 5 g/ml (Sigma)
was placed on 293 cells for 5 h, 50 l of fresh medium was added, and the plate
was incubated overnight at 37°C. On the next day, the viral inoculum was
removed and fresh medium was added. Infectivity was determined 2 days postinfection by counting the number of GFP-expressing cells by fluorescence microscopy as described previously (19).
Sample preparation for KSHV quantitative TaqMan PCR. 293 cells were
cotransfected with various combinations of KSHV BAC genomes and plasmids
pRTA, pCDNA3.1, and pCDNAK8.1. All transfections contained the same
amount of total DNA transfected. The amount of BAC36 or BAC⌬K8.1 remained constant, while various amounts of pCDNA3.1 (control), RTA-expressing plasmid pRTA, and complementing plasmid pCDNAK8.1 were used. TPA
(25 ng/ml) and alpha interferon (1,000 U/ml) were added 24 h posttransfection
to enhance viral induction. Supernatants were centrifuged three times at 5,000 ⫻
g for 15 min to remove floating cells. Supernatants collected after centrifugation
were subsequently treated with TurboDNase (Ambion Inc., Austin, Tex.) for 3 h
at 37°C to ensure that nonencapsidated genomes were not present during the
real-time PCR assay. In these experiments, 1 U of TurboDNase was used per 100
l of sample. In control experiments, 1 U of TurboDNase reduced the level of
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TABLE 1. Synthetic oligonucleotide primers and TaqMan probe

Designation

Primer sequence

Name

Purpose and product size

5⬘-CAATATTAAAGGGACCCAAGTTAATCCCTTAATCCTCTGGGAT
TAATAACCATGAGTTAGCCACGTTGTGTCTCAAAATCTCTGAT
GTTA-3⬘
5⬘-CTAGCACAGGTAAAGTATAAGGACAAGTCCCAGCAATAAACC
CACAGCCCATAGTATGTACGGTTGATGA-3⬘

GET recombination (1.2 kb)

5⬘K8.1/up
3⬘K8.1/nostop

5⬘-CATGCTGATGCGAATGTGCCA-3⬘
5⬘-CACTATGTAGGGTTTCTTACG-3⬘

Diagnostic PCR for BAC36 (wild type)
(964 bp) and BAC36⌬K8.1 (1.4 kb)

E
F

5⬘KanFwd
3⬘KanRev

5⬘-ATGAGCCATATTCAACGG-3⬘
5⬘-CTCATCGAGCATCAAATG-3⬘

Kanamycin probe (1.1 kb)

G
H

5⬘ORF37-Fwd
3⬘ORF37-Rev

5⬘-TCGGTGGCGATGCTTTAGAC-3⬘
5⬘-TGAAGCAGACGATGCTTTGC-3⬘

TaqMan PCR product (99 bp)

I

ORF37-FAM

5⬘-TCGTAACCCCCGTCTACTTTCCCCG-3⬘

TaqMan FAM probe

J
K

K8.1F
K8.1R

5⬘-TAACCATGAGTTCCACACAGATTC-3⬘
5⬘-GGTTTTGTGTTACACTATGTAGG-3⬘

K8.1A PCR product (763 bp)

A

5⬘K8.1/KanF

B

3⬘K8.1/KanR

C
D

BAC36 DNA by more than 1,000-fold, as determined by TaqMan PCR. Viral
DNA from supernatants was extracted in triplicate by using a standard proteinase K-phenol-chloroform protocol.
KSHV TaqMan PCR quantitation. Reagents and enzymes used for TaqMan
PCR were obtained from PE Applied Biosystems (Foster City, Calif.). The
sequences for the TaqMan FAM probe and ORF37 primers used for the quantitative detection of KSHV molecules were published previously (52) and are
listed in Table 1. Each 25-l PCR mixture contained TaqMan universal PCR
master mix and 0.25 l of 20 M primer stock for both forward and reverse
primers. The ORF37-FAM probe (100 M) was diluted 1:50, and 0.25 l of the
probe was used per reaction. The reaction conditions were as follows: 2 min at
50°C, 10 min at 95°C, and 40 cycles at 95°C for 15 s and 60°C for 1 min (two-step
PCR). During amplification, an ABI-Prism 7700 sequence detector monitored
real-time PCR amplification by quantitatively analyzing fluorescence emissions.
Samples were analyzed in triplicate in three independent runs. The Ct value was
defined as the cycle number in which the fluorescence detected exceeded an
established threshold level that was kept constant in all experiments (21).
The concentration of BAC36 DNA after purification with the large-construct
kit was determined by measuring the optical density at 260 nm and by comparative gel electrophoresis with known amounts of molecular markers. Serial 10fold dilutions of BAC36 DNA were used as controls to construct a standard
curve based on the Ct value and logarithmic amounts of diluted BAC36. The
number of KSHV genomes in each specific supernatant sample was determined
by comparison of the obtained Ct value to the corresponding value of the
standard curve reflecting a specific amount of KSHV DNA. The number of
genomes within this specific amount of viral DNA was obtained by using the
following relationship: one KSHV genome was approximately equal to 0.197 fg.

tion of the kanamycin resistance gene cassette produced multiple stop codons in different frames immediately downstream
of the ATG codon, preventing the expression of any aberrant
proteins. The 3⬘ primer (primer B; Table 1 and Fig. 1A) is located approximately 90 nucleotides upstream of the TAA stop
codon of K8.1 (Fig. 1B).

RESULTS
Construction of KSHV BAC36⌬K8.1. The complete KSHV
genome was recently cloned into a BAC, yielding BAC36 and
enabling the genetic manipulation of the KSHV genome in E.
coli. BAC36 constitutively expresses the GFP gene, allowing
the detection of eukaryotic cells containing KSHV genomes
(61). The BAC-based GET homologous recombination system
was used to construct a large deletion within the K8.1 gene in
E. coli. Deletion of most of the K8.1 gene was accomplished by
targeting the K8.1 ORF with specific primers as detailed in
Materials and Methods. The genomic region encompassing the
K8.1 gene codes for K8.1A and K8.1B by means of spliced
transcripts. The 5⬘-most primer (primer A; Table 1 and Fig.
1A) used for homologous recombination overlaps the K8.1
ATG and extends into the K8.1 ORF by 6 nucleotides. Inser-

FIG. 1. (A) Schematic illustration of the GET homologous recombination system BAC36⌬K8.1 DNA. A PCR fragment containing the
kanamycin resistance gene flanked by 60 bp of K8.1 upstream and
3⬘-end sequences was used to construct BAC36⌬K8.1 DNA recombinants containing the kanamycin resistance gene cassette within the
targeted genomic site. The primer binding sites of the majority of the
primers (Table 1) used to create the BAC36⌬K8.1 DNA are shown.
Seq., sequence. (B) Schematic representation of the ORF50 gene locus
and the relevant transcript for ORF50 as described previously (58).
Vertical broken lines indicate the deleted genomic region encompassing most of the K8.1 ORF. The relative location of each gene and the
locations of splice donor (SD) and splice acceptor (SA) sites are
indicated.
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The BAC36⌬K8.1 construct was tested for the presence of
the engineered insertion by diagnostic PCR and Southern blotting (Fig. 2). Primers C and D (Table 1 and Fig. 1A), located
immediately upstream of the K8.1 gene and within the 3⬘ nondeleted portion of the K8.1 ORF, respectively, were used to
amplify a diagnostic DNA fragment from KSHV DNA purified
from BCBL-1 cells, BAC36 DNA, and BAC36⌬K8.1 DNA
(Fig. 2A). DNA from BCBL-1 cells and BAC36 DNA produced a predicted DNA fragment of 964 bp. In contrast, amplification of the targeted region of BAC36⌬K8.1 DNA produced a DNA fragment of approximately 1.4 kbp, as predicted
after insertion of the kanamycin resistance gene cassette. Further confirmation of the genetic content of BAC36⌬K8.1 was
obtained by restriction endonuclease fragment analysis and
Southern blotting (Fig. 2B). Restriction enzyme analysis of
BAC36 DNA and BAC36⌬K8.1 DNA with KpnI revealed similar DNA fragmentation patterns, with the exception that a
DNA fragment of approximately 4.6 kbp was absent from the
BAC36⌬K8.1 profile but was present in the BAC36 restriction
pattern. In addition, the BAC36⌬K8.1 pattern included a new
DNA fragment migrating with an apparent size of approximately 5 kbp, in agreement with the theoretical size of a new
DNA fragment produced after insertion of the kanamycin resistance gene cassette within the K8.1 gene (Fig. 2B, panel 1).
Southern blotting with a biotinylated kanamycin resistance
gene probe for KpnI-digested BAC36 DNA and BAC36⌬K8.1
DNA revealed the presence of a unique kanamycin insertion
within a DNA KpnI fragment of approximately 5 kbp, while
there was no reaction of the probe with the BAC36 DNA. A
prebiotinylated molecular weight ladder was used for DNA
fragment size determination (Fig. 2B, panel 2). These results
are consistent with the insertion of the kanamycin resistance
gene cassette within the K8.1 gene and with the deletion of
most of the K8.1 ORF.
Transient expression of K8.1A. The K8.1 gene was cloned
into the transient expression plasmid pCDNA3.1 and expressed in 293 cells by transfection. Detection of the transiently expressed K8.1A glycoprotein was achieved by indirect
immunofluorescence with anti-K8.1 MAb 19B4 (Fig. 3A, panel
A) (60). Approximately, 50% of the transfected cells reacted
strongly with anti-K8.1 MAb 19B4, while mock-transfected
cells failed to react in immunofluorescence assays (Fig. 3A,
panels B and D). Similar results were produced by immunohistochemical staining of 293 cells transfected with plasmid
pCDNAK8.1A (Fig. 3A, panel C). To further characterize the
expression of K8.1A under transient expression conditions,
lysates of 293 transfected cells were electrophoretically separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and tested by immunoblotting with MAb 19B4, and
the expression of K8.1 was compared to that in BCBL-1 cells
after TPA induction (Fig. 3B). Transiently expressed K8.1A
migrated with an apparent molecular mass of 37 kDa, while
BCBL-1 cells expressed K8.1 migrating with molecular masses
ranging from 34 to 37 kDa (Fig. 3B, lanes 2 and 3). The 37-kDa
glycoprotein species has been shown to represent fully glycosylated K8.1 glycoprotein (44). MAb 19B4 reacted with proteins of higher apparent molecular masses presumably corresponding to higher-order multimers of K8.1 (60).
Characterization of latent and lytic gene expression. Logphase 293 cells were transfected with BAC36 or BAC36⌬K8.1

J. VIROL.

FIG. 2. Genomic analysis of BAC36⌬K8.1 DNA. (A) PCR assay to
confirm the deletion of the K8.1A gene in BAC36. Amplification of the
K8.1 region produced a 964-bp band from both BCBL-1 and BAC36
DNAs; the mutant BAC36⌬K8.1 DNA showed a band of 1,405 bp due
to the size difference from deletion or insertion mutagenesis. Lane M,
molecular size markers. (B, panel 1) Restriction fragment analysis of
BAC36⌬K8.1 DNA and wild-type BAC36 DNA. The KpnI restriction
pattern of BAC36⌬K8.1 DNA was compared to that of wild-type
BAC36 DNA. As predicted from the KpnI restriction pattern, the
introduction of the kanamycin resistance gene into BAC36 led to an
increase in size from an estimated 4.5-kb fragment to a 4.9-kb fragment
(arrow). (B, Panel 2). Southern blot analysis of BAC36⌬K8.1 DNA.
The KpnI restriction fragment from panel 1 was hybridized with a
probe derived from a kanamycin PCR product that was labeled with
biotin. A biotinylated kanamycin probe hybridized to a 4.9-kb KpnI
DNA fragment that was absent in wild-type BAC36 DNA (arrow).
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FIG. 3. Detection of K8.1A gene expression in transiently transfected cells. (A) Immunofluorescence (panel A) and immunohistochemical staining (panel C) of 293 cells transiently transfected with
K8.1A. Immunofluorescence (panel B) and immunohistochemical reactivities (panel D) of mock-transfected 293 cells. (B) Immunoblot of
lysates from mock-transfected cells (lane 1), cells transiently transfected with K8.1A (lane 2), and induced BCBL-1 cells (lane 3).

DNA, and the profiles of expression of the LANA latent gene
and lytic genes ORF59 and K8.1 were assessed by immunohistochemical staining with MAbs specific for each protein (Fig.
4). Typically, BAC36⌬K8.1 DNA transfected more cells (20 to
30%) than did BAC36 DNA (10 to 15%). In the absence of
TPA induction, the anti-LANA antibody reacted with cells
transfected with either BAC36 or BAC36⌬K8.1 DNA (Fig. 4F
and L). Similar results were obtained after transfected 293 cells
were induced with TPA (Fig. 4I and O). Immunostaining of
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transfected 293 cells with the anti-ORF59 antibody detected
the expression of ORF59 (lytic gene) in either the absence
(Fig. 4E and K) or the presence (Fig. 4H and N) of TPA induction, although after TPA induction, approximately twofold
more cells stained positively for ORF59. Similar results were
obtained with anti-K8.1 MAb immunostaining, with the exception that K8.1A was not expressed in 293 cells transfected with
BAC36⌬K8.1 DNA (Fig. 4J and M). No reactivity was observed between the anti-K8.1, anti-ORF59, or anti-LANA antibody and mock-transfected 293 cells (negative control) (Fig.
4A, B, and C).
Production of infectious KSHV by BAC36 DNA- and
BAC36⌬K8.1 DNA-transfected 293 cells. To assess the role of
K8.1 in virus infectivity, purified BAC36 DNA and BAC36⌬K8.1
DNA were cotransfected with a plasmid transiently expressing
the RTA (ORF50) gene and either pCDNA3.1 (control plasmid) or pCDNAK8.1 (complementing plasmid). The number
of transfected cells expressing GFP remained constant in the
presence or absence of the RTA-expressing plasmid (data not
shown). RTA is the major KSHV transactivator protein and is
capable of inducing the lytic replication of KSHV (54). KSHV
lytic replication was further enhanced through the addition of
TPA and alpha interferon for 5 days, at which point supernatants
of transfected cells were clarified of cellular debris and tested for
the presence of infectious KSHV. The relative infectivities of
supernatant viruses were determined by monitoring the number
of GFP-expressing cells (see Materials and Methods) after infection of 293 cells (19) (Fig. 5A, panels A, B, and C).
Control experiments were also performed in parallel to determine whether cellular debris from transfected cells carried
over GFP during the infection process. 293 cells were transfected with plasmids pRTA, pCDNA3.1, and pEGFP-C1 (constitutively expressing GFP). Extracellular fluids were treated in
a manner similar to those containing infectious viruses and were
tested for their ability to produce GFP-expressing cells under
similar infection conditions. These control experiments revealed
no GFP carryover from ruptured cells (Fig. 5A, panels D).
Transfection experiments performed in triplicate revealed
that BAC36 DNA and BAC36⌬K8.1 DNA consistently produced, on average, 260 and 460 GFP-expressing cells/ml, respectively. Cotransfection of BAC36⌬K8.1 DNA with complementing plasmid pCDNAK8.1 seemed to enhance infectious
virus production by approximately twofold (Fig. 5B). Cotransfection of BAC36 DNA with pCDNAK8.1 or other control
plasmids did not have an effect on infectious virus production.
Furthermore, different isolates of BAC36 or BAC36⌬K8.1 exhibited similar infectivities (data not shown).
Quantitation of KSHV by TaqMan PCR. To better quantify
the amount of virus produced by transfection of 293 cells, a
real-time PCR assay targeting the ORF37 gene was used essentially as described previously (52). The relative amounts of
BAC36 DNA and BAC36⌬K8.1 DNA found in supernatants
of transfected 293 cells were obtained from a standard curve
based on known amounts of BAC36 DNA (see Materials and
Methods). All BAC-transfected 293 cells produced relatively
large numbers of genome equivalents in supernatants (Fig. 6).
The number of BAC36⌬K8.1 genomes found in supernatants
of transfected cells was consistently higher than that of BAC36
genomes, in part due to the higher transfection efficiency of
BAC36⌬K8.1 DNA than of BAC36 DNA (data not shown).
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FIG. 4. Latent and lytic gene expression profiles for uninduced and induced 293 cells transfected with either BAC36 DNA or BAC36⌬K8.1
DNA. Transfections with BAC36⌬K8.1 DNA did not result in any expression of a K8.1A gene product after RTA and TPA induction (J and M).
As a positive control, 293 cells transiently transfected with BAC36 DNA were reacted with an anti-K8.1A antibody (D and G). The anti-ORF59
MAb reacted with uninduced or induced (TPA plus RTA) 293 cells transfected with BAC36⌬K8.1 DNA (K and N) or BAC36 DNA (E and H).
Similarly, the anti-LANA MAb reacted with uninduced or induced 293 cells transfected with BAC36 DNA (panels F and I) or BAC36⌬K8.1 DNA
(L and O). Mock-transfected 293 cells failed to show any reactivity with the anti-K8.1, anti-ORF59, and anti-LANA MAbs (A, B, and C,
respectively). Arrows indicate K8.1, ORF59, or LANA expression in 293 cells.

Cotransfection of plasmid pCDNAK8.1A with BAC36⌬K8.1
produced approximately two- to threefold more viral genomes
in 293 cell supernatants than did transfection with BAC36⌬K8.1
alone (Fig. 6). This effect was pCDNAK8.1 specific, since cotransfection of BAC36⌬K8.1 DNA with vector plasmid pCDNA3.1
did not increase the number of viral genomes found in supernatants (Fig. 5B).
Viral genomes in supernatants were protected from TurboDNase treatment, indicating that most of the viral genomes in
293 cell supernatants were encapsidated (Fig. 6). These results
were most likely not due to differences in transfection efficiencies, since the number of transfected cells expressing the viral
GFP gene remained approximately constant in the presence or

absence of complementing plasmid pCDNAK8.1A (data not
shown). Therefore, the two- to threefold increase in the number of encapsidated KSHV genomes with a deletion of K8.1 in
supernatants from cells transfected with pCDNAK8.1A, compared to the number seen with transfection with BAC36⌬K8.1
alone, was probably due to the production of a larger number
of encapsidated KSHV virions (Fig. 6).
DISCUSSION
Viral glycoproteins encoded by herpesviruses are important
determinants of viral infectivity and spread. Although there are
significant differences among herpesviruses belonging to the
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FIG. 5. Relative infectivities of KSHV mutants. 293 cells were infected with viruses obtained from supernatants of 293 cells transfected with
BAC36 DNA and BAC36⌬K8.1 DNA. (A) Approximately 104 293 cells per well in a 96-well plate were incubated with 50 l of supernatant
containing virus obtained from transfections of 293 cells with BAC36, pRTA, and pCDNA3.1 (panel A2), BAC36⌬K8.1, pRTA, and pCDNA3.1
(panel B2), BAC36⌬K8.1, pRTA, and pCDNAK8.1 (panel C2), or pEGFP-C1, pRTA, and pCDNA3.1 (panel D2). Matching phase-contrast
images are shown in panels A1, B1, C1, and D1. (B) Virus infectivity was determined by measuring the number of GFP-expressing cells. Error bars
indicate standard deviations. All experiments were performed in triplicate. Infectious virions were obtained from 293 cells transfected with DNA
mixtures as shown.

three herpesvirus subfamilies—alpha, beta, and gamma—
there are important similarities among all herpesviruses with
regard to virus entry into cells and egress from infected cells.
Generally, all herpesviruses require initial attachment to cell
surfaces, often mediated by binding to ubiquitous glycosaminoglycans, such as heparan sulfate. Virus penetration is
achieved by means of either direct fusion of viral envelopes
with cellular membranes or virion endocytosis and subsequent
fusion of viral envelopes with endosomal membranes, releasing
capsids into the cytoplasm of infected cells. For KSHV, initial
attachment to cell surfaces is mediated by the binding of gB
and glycoprotein K8.1 to heparan sulfate moieties (2, 4, 7, 57).
In addition, gB binds to the ␣3␤1-integrin receptor, which is

thought to facilitate virus penetration into certain cells by
means of endocytosis (3). The role of K8.1A in virus infectivity
is not immediately apparent, since an initial report indicated
that soluble K8.1A substantially inhibited virion attachment to
cells (57), while a later report suggested that a similar soluble
form of K8.1A did not inhibit virus infectivity. In this report,
we directly addressed the role of K8.1 in virus infectivity by generating a KSHV recombinant with a deletion of both spliced
variants of the K8.1 gene. Characterization of this mutant virus
in 293 cell culture assays revealed that K8.1 genes were not
essential for virus entry.
The BAC36⌬K8.1 virus was made by using the GET homologous recombination system to insert a gene cassette coding
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FIG. 6. Quantitative, real-time PCR assay for determination of
KSHV genomes in supernatants of transfected 293 cells. Supernatants
were either treated (gray bars) or not treated (black bars) with DNase
I. Viral DNA extraction and real-time PCR were performed in triplicate with supernatants obtained from cells transfected with either
BAC36, BAC36⌬K8.1, or BAC36⌬K8.1 DNA and various plasmid
mixtures. Supernatants from 293 cells transfected with pEGFP-C1,
pCDNA3.1, and pRTA were included as a negative control. Error bars
indicate standard deviations.

for kanamycin resistance within the BAC36K8.1 genomic region. The K8.1 gene deletion spanned the K8.1 ORF immediately after the initiation codon (ATG) and extended to approximately 90 bases upstream of the K8.1 termination codon.
KSHV ORF50, specifying the major lytic transactivator RTA,
and the K8 ORF specifying K-bZIP, which has been suggested
to act either as a repressor of lytic replication (23, 28) or as a
replication activator protein (59), lie immediately 5⬘ to the
K8.1 gene. All three genes code for mRNAs that utilize the
same polyadenylation signal immediately downstream of K8.1.
The engineered deletion of K8.1 removes the last splice acceptor site and, consequently, prevents splicing of the 3⬘-most
exon. It is possible that the resultant 3⬘ modification of the
RTA and K8 mRNAs adversely affects the expression of these
proteins. To ensure that the transfected BAC36⌬K8.1 DNA
could enter lytic replication, a plasmid capable of the transient
expression of RTA was cotransfected with BAC36⌬K8.1 DNA.
Consistently, BAC36⌬K8.1 DNA produced three- to fivefold
more infectious virus than BAC36 DNA. A possible explanation for this result is that deletion of the terminal exon of
K-bZIP (K8) reduced its expression, allowing for improved
trans-activation by the exogenously provided RTA.
KSHV genomes remain latent in BCBL-1 cells and could be
activated for lytic replication, as evidenced by the expression of
lytic proteins, such as those encoded by ORF59 and K8.1 after
induction with TPA and/or exogenously provided RTA. Trans-
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fection experiments with 293 cells revealed that both BAC36
and BAC36⌬K8.1 genomes expressed a low level of ORF59,
indicating that under transient transfection conditions, some
viral genomes may be activated for lytic replication in the
absence of exogenously provided TPA or RTA; this notion is
consistent with previous observations (61). These results are
also in agreement with recent observations that infection of
primary human umbilical vein endothelial cell cultures occurs
in two phases: (i) a permissive phase, in which the cultures
undergo active viral lytic replication and infectious virus production; and (ii) a latent phase, in which the surviving cells
from the lytic phase switch to latent infection, with a small
number of cells undergoing spontaneous viral lytic replication
(19). However, in most experiments, trans-activation by RTA
produced at least two- to threefold more cells in which KSHV
replicated in a lytic phase, as evidenced by the expression of
the ORF59 and K8.1 genes. As expected, BAC36⌬K8.1 failed
to express any K8.1 under either induced or uninduced conditions.
Transfection of either BAC36 DNA or BAC36⌬K8.1 DNA
into 293 cells produced infectious virions in the supernatants of
the transfected cells. The number of infectious virions produced by the BAC36⌬K8.1 DNA transfection in triplicate (Fig.
5B) was higher than that obtained with BAC36 DNA. This
difference was largely due to the lower transfection efficiency
obtained with BAC36 DNA (approximately 15% of 293 cells
expressed GFP) than with BAC36⌬K8.1 DNA (approximately
30% of 293 cells expressed GFP), as determined by measuring
the number of GFP-expressing cells (data not shown). Cotransfection of BAC36⌬K8.1 DNA with plasmid pCDNAK8.1A,
transiently expressing the K8.1 glycoprotein, consistently
produced approximately twofold larger numbers of infectious virions in extracellular fluid than did transfections with
BAC36⌬K8.1 DNA and pCDNA3.1 (control). This result was
not due to differences in transfection efficiencies between
BAC36⌬K8.1 DNA-pCDNA3.1 and BAC36⌬K8.1 DNApCDNAK8.1 tranfections, because both transfections produced
equivalent numbers of GFP-expressing 293 cells. In addition,
supernatants from 293 cells transfected with a plasmid expressing GFP (pEGFP-C1) and pCDNA3.1 did not produce any
GFP-positive cells, indicating that there was no GFP carryover
by potentially ruptured cells. These results indicate that K8.1 is
not needed for virus entry, since BAC36⌬K8.1 virions remain
infectious in the absence of K8.1.
To differentiate the complementation effect of transiently
expressed K8.1 on BAC36⌬K8.1 infectious virus production,
the number of KSHV genomes contained in extracellular fluid
of transfected 293 cells was determined by real-time PCR.
Cotransfection of BAC36⌬K8.1 with complementing plasmid
pCDNAK8.1 consistently produced larger numbers of viral
genome equivalents in supernatants than did cotransfection of
BAC36⌬K8.1 with pCDNA3.1. These genomes represented
encapsidated DNA, since treatment with DNase I did not
appreciably reduce the number of KSHV genomes, suggesting
that K8.1 enhanced infectious virus production.
Previous studies addressing the role of K8.1A in virus attachment showed that a soluble version of K8.1A reduced
KSHV attachment by as much as 70% (57). In a latter study, a
similar soluble form of K8.1A did not affect virus infectivity
(7). In this report, we conclusively show that K8.1 is not nec-

Downloaded from https://journals.asm.org/journal/jvi on 18 January 2022 by 2620:105:b001:1060:86f:667c:32f5:4ae9.

6396

KSHV GLYCOPROTEIN K8.1

essary for virus infectivity, in agreement with the latter study
mentioned above. The relative increase in the number of encapsidated KSHV virions after transient expression of K8.1
suggests that K8.1 may facilitate virion morphogenesis. A similar scenario may occur for EBV gp350/220, since deletion of
the gp350/220 gene caused a decrease in infectivity which was
complemented in trans by exogenously supplied gp350/220
(24).
Characteristically, KSHV produces a large number of noninfectious virions in supernatants of BCBL-1 cells after induction to enter lytic replication. In one study, it was calculated
that approximately 107 genome equivalents were produced per
1 ml of BCBL-1 cell suspension culture at 48 h after TPA induction (46). However, typically, a very small portion of these
viruses enter susceptible cells and initiate a viral infection, as
evidenced by the expression of either latent or lytic genes (A.
Baghian, R. E. Luna, and K. G. Kousoulas, unpublished data).
Similarly, BAC36 and BAC36⌬K8.1 transfections produced a
relatively large number of encapsidated genomes in the supernatants of transfected cells; however, a very small percentage
of these virions were infectious, as evidenced by the expression
of the virus-encoded GFP gene after infection of 293 cells. It is
unclear at this time why KSHV produces such a large number
of noninfectious viruses, which are presumably defective in
one or more functions. One possibility is that 293 cells do not
support efficient cytoplasmic morphogenesis and egress, resulting in a high percentage of partially defective virions in supernatant fluids. The production of high-titer infectious KSHV
should enable ultrastructural visualization of egressing KSHV,
visualization of the intracellular sites used by the virus, and
dissection of the roles of individual glycoproteins in efficient
morphogenesis and egress.
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